| Literature DB >> 30002718 |
Min Jung Kim1, Da-Hye Lee1,2, Jiyun Ahn1,2, Tae-Youl Ha1,2, Young Jin Jang1, Eunju Do3, Chang Hwa Jung1,2.
Abstract
Although classification of an individual's Sasang constitution is a key step in the prescription of traditional Korean medicine, the classifying process is complex and not objective. Identification of metabolic-based biomarkers could allow the development of a reliable and sensitive classification technique and even therapeutic management. Our pilot study investigated whether metabolites in plasma are characteristic of Sasang constitutions. Ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolic analysis was conducted against 15 Soyangin (SY), 15 Taeeumin (TE), and 18 Soeumin (SE) individuals, as classified according to the Questionnaire for Sasang Constitution Classification II (QSCC II) and specialist diagnosis. Metabolomics data showed that the TE group was significantly separated from the SY and SE groups. Nine canonical pathways related to constitution; phenylalanine metabolism, aminoacyl-tRNA, tyrosine, and tryptophan biosynthesis were activated in the TE group as compared with the other groups. Similar to the results of the metabolomics analysis, the TE group was also significantly separated from the other two groups by lipidomic analysis. On the other hand, the intensity of lipid metabolites was higher in the SY group than in the other groups. Our findings suggest that the combined analysis of metabolomics and lipidomics can provide useful information for characteristics of Sasang constitutions.Entities:
Year: 2018 PMID: 30002718 PMCID: PMC5998192 DOI: 10.1155/2018/9214960
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
General characteristics of participants.
| Variable | SY | TE | SE |
|
|---|---|---|---|---|
| No. of participants | 15 | 15 | 18 | |
| Age (year) | 24.07 ± 2.71 | 24.33 ± 2.02 | 23.67 ± 1.68 | 0.670 |
| BMI (kg/m2) | 25.09 ±2.21b | 25.57 ± 1.90b | 21.36 ± 1.75a | <0.0001 |
| BFP (%) | 22.65 ± 4.34b | 24.02 ± 4.06b | 19.08 ± 4.79a | 0.007 |
| WHR | 0.87 ± 0.03b | 0.86 ± 0.04b | 0.83 ± 0.03a | 0.003 |
| VFA | 81.91 ± 28.34b | 86.55 ± 19.62b | 60.54 ± 25.64a | 0.009 |
| Glucose (mg/dL) | 92.20 ± 7.59 | 90.20 ± 4.04 | 91.61 ± 9.10 | 0.747 |
| TC (mg/dL) | 161.20 ± 32.74a | 186.60 ± 26.28b | 168.67 ± 27.47ab | 0.060 |
| TG (mg/dL) | 126.87 ± 138.15 | 111.33 ± 65.40 | 74.22 ± 37.86 | 0.220 |
| SGOT | 22.73 ± 6.72ab | 26.60 ± 11.63b | 19.50 ± 4.42a | 0.048 |
| SGPT | 33.87 ± 11.69 | 29.80 ± 13.21 | 24.39 ± 9.57 | 0.069 |
|
| 32.00 ± 11.59 | 28.40 ± 13.28 | 26.17 ± 10.10 | 0.363 |
| Protein (g/dL) | 7.51 ± 0.26 | 7.57 ± 0.27 | 7.36 ± 0.30 | 0.090 |
| Albumin (g/dL) | 4.67 ± 0.23 | 4.77 ± 0.24 | 4.76 ± 0.29 | 0.532 |
| SBP (mmHg) | 127.40 ± 9.93b | 126.27 ± 11.51b | 117.56 ± 10.18a | 0.018 |
| DBP (mmHg) | 81.40 ± 8.77 | 81.47 ± 8.59 | 77.94 ± 7.77 | 0.382 |
| WBC (×103/ | 6.03 ± 1.46 | 5.82 ± 1.32 | 5.94 ± 1.55 | 0.922 |
| RBC (×106/ | 4.94 ± 0.43 | 5.11 ± 0.35 | 4.82 ± 0.40 | 0.121 |
| PLT (×103/ | 261.87 ± 54.80 | 243.73 ± 43.89 | 235.17 ± 42.61 | 0.271 |
SY: Soyangin; TE: Taeeumin; SE: Soeumin; BMI: body mass index; BFP: body-fat percentage; WHR: waist-to-hip ratio; VFA: visceral fat area; TC: total cholesterol; TG: triglycerides; SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic-pyruvic transaminase; γ-GPT: gamma-glutamyl transferase; SBP: systolic blood pressure; DBP: diastolic blood pressure; WBC: white blood cell; RBC: red blood cell; PLT: platelet cell. Differences among groups were analyzed using Duncan's multiple range test (p < 0.05) and are indicated by different lowercase letters (a, b, and ab). Letter “a” is significant to “b,” but “ab” is not significant. ∗, ∗∗, and ∗∗∗∗ denote one-way ANOVA (parametric test).
Figure 1Partial least-squares discriminant analysis (PLS-DA) score and permutation results from plasma metabolites of participants classified according to Sasang constitution types based on metabolomics analysis. (a) PLS-DA score plot in ESI- mode. (b) Validation plot in ESI- mode. (c) PLS-DA score plot in ESI+ mode. (d) Validation plot in ESI+ mode. SY: Soyangin; TE: Taeeumin; SE: Soeumin.
List of potential plasma biomarkers in three Sasang constitutions.
| No. | Tentative metabolites | m/z | Mass error | Adduct | Fold change |
| Pathway | ||
|---|---|---|---|---|---|---|---|---|---|
| SY/SE | SY/TE | SE/TE | |||||||
| 1 | Lactic acid | 89.0235 | M-H | 1.49 | 1.19 | 0.80 | 0.090 | Propanoate metabolism | |
| 2 | 3-Hydroxybutyric acid | 103.0388 | -0.69 | M-H | 0.89 | 0.61 | 0.68 | 0.020 | Synthesis and degradation of ketone bodies |
| 3 | Valine | 118.0737 | -13.13 | M+H | 1.01 | 0.85 | 0.85 | 0.076 | Aminoacyl-tRNA biosynthesis |
| 4 | 4-Hydroxybenzaldehyde | 121.0285 | -0.53 | M-H | 0.92 | 0.81 | 0.75 | 0.041 | Phenylalanine metabolism |
| 5 | Benzoic acid | 123.0437 | -0.94 | M+H | 1.15 | 1.17 | 1.02 | 0.115 | Phenylalanine metabolism |
| 6 | Pyrrolidonecarboxylic acid | 128.0341 | -0.73 | M-H | 0.98 | 0.78 | 0.77 | 0.068 | D-glutamine and D-glutamate metabolism |
| 7 | Glutamic acid | 130.0376 | -12.79 | M+H-H2O | 0.89 | 0.79 | 0.89 | 0.000 | Aminoacyl-tRNA biosynthesis |
| 8 | Ornithine | 131.0811 | -0.96 | M-H | 0.88 | 0.86 | 0.98 | 0.071 | Glutathione metabolism |
| 9 | Leucine | 132.0883 | -14.17 | M+H | 0.88 | 0.45 | 0.40 | 0.002 | Aminoacyl-tRNA biosynthesis |
| 10 | Glutaric acid | 133.0562 | 6.11 | M+H | 0.92 | 0.84 | 0.92 | 0.045 | Lysine degradation |
| 11 | Adenine | 136.0622 | -0.12 | M+H | 0.93 | 0.89 | 0.96 | 0.094 | Purine metabolism |
| 12 | Phenylacetamide | 136.0632 | -7.00 | M+H | 0.85 | 0.83 | 0.98 | 0.084 | Phenylalanine metabolism |
| 13 | Lysine | 145.0953 | -2.37 | M-H | 1.18 | 1.10 | 0.93 | 0.105 | Aminoacyl-tRNA biosynthesis |
| 14 | Phenyllactic acid | 147.0440 | -0.63 | M-H2O-H | 0.88 | 0.89 | 0.99 | 0.038 | Phenylalanine and tyrosine metabolism |
| 15 | Methionine | 148.0421 | -1.10 | M-H | 0.91 | 0.83 | 0.92 | 0.265 | Aminoacyl-tRNA biosynthesis |
| 16 | Caffeic acid | 163.0296 | -9.86 | M+H-H2O | 0.38 | 0.40 | 0.94 | 0.000 | Phenylpropanoid biosynthesis |
| 17 | Hydroxyphenyllactic acid | 163.0390 | -0.51 | M-H2O-H | 0.95 | 0.80 | 0.84 | 0.157 | Ubiquinone and other terpenoid-quinone biosynthesis |
| 18 | Phenylalanine | 164.0701 | -1.08 | M-H | 0.87 | 0.88 | 0.99 | 0.019 | Phenylalanine metabolism |
| 19 | Phenylpyruvic acid | 165.0420 | -13.20 | M+H | 0.87 | 0.85 | 0.97 | 0.094 | Phenylalanine metabolism |
| 20 | Hippuric acid | 178.0494 | -3.80 | M-H | 0.47 | 0.68 | 0.96 | 0.045 | Phenylalanine metabolism |
| 21 | Tyrosine | 180.0652 | -0.93 | M-H | 0.85 | 0.88 | 0.96 | 0.045 | Phenylalanine metabolism |
| 22 | 3-Indolepropionic acid | 190.0737 | -7.10 | M+H | 0.36 | 0.66 | 0.54 | 0.247 | |
| 23 | 7-Methyluric acid | 203.0191 | 1.05 | M+Na-2H | 0.89 | 0.86 | 0.96 | 0.024 | Caffeine metabolism |
| 24 | Indole-3-lactic acid | 204.0640 | -2.15 | M-H | 1.07 | 1.05 | 0.98 | 0.07 | Tryptophan metabolism |
| 25 | Acetylcarnitine | 204.1108 | -12.79 | M+H | 0.93 | 0.84 | 0.76 | 0.017 | Fatty acid metabolism (acyl carnitine) |
| 26 | Propionylcarnitine | 218.1265 | -12.67 | M+H | 0.67 | 0.83 | 0.80 | 0.033 | Fatty acid metabolism (acyl carnitine) |
| 27 |
| 227.1272 | -1.14 | M-H | 0.87 | 0.67 | 0.77 | 0.053 | |
| 28 | Melatonin | 231.1222 | 8.82 | M-H | 0.99 | 0.58 | 0.59 | 0.063 | Tryptophan metabolism |
| 29 | Hexanoylcarnitine | 260.1748 | -11.40 | M+H | 0.75 | 0.83 | 0.90 | 0.042 | Fatty acid metabolism (acyl carnitine) |
| 30 | Octanoylcarnitine | 288.2072 | -10.32 | M+H | 0.68 | 0.65 | 0.95 | 0.033 | Fatty acid metabolism (acyl carnitine) |
| 31 | 5a-Tetrahydrocorticosterone | 315.2278 | -4.6 | M+H-2H2O | 0.94 | 0.84 | 0.89 | 0.090 | |
| 32 | Decanoylcarnitine | 316.2402 | -8.55 | M+H | 0.72 | 0.71 | 0.99 | 0.071 | Fatty acid metabolism (acyl carnitine) |
| 33 | Stearoylcarnitine | 428.3683 | 2.29 | M+H | 1.00 | 0.85 | 0.86 | 0.047 | Fatty acid metabolism (acyl carnitine) |
SY: Soyangin; TE: Taeeumin; SE: Soeumin. Fold change was calculated by dividing the mean of the peak intensity of each metabolite from each of the two groups. p < 0.05; P < 0.01; P < 0.001.
Figure 3Heat map and metabolic pathway of metabolites identified by metabolomics and lipidomics analysis. (a) Heat map of identified metabolites. (b) Amino acid metabolism. (c) Lipid metabolism. SY: Soyangin; TE: Taeeumin; SE: Soeumin.
Figure 2Partial least-squares discriminant analysis (PLS-DA) score and permutation results from plasma metabolites of participants classified according to Sasang constitution types using lipidomics analysis. (a) PLS-DA score plot in ESI- mode. (b) Validation plot in ESI- mode. (c) PLS-DA score plot in ESI+ mode. (d) Validation plot in ESI+ mode. SY: Soyangin; TE: Taeeumin; SE: Soeumin.
Circulating lipid profiles in the three Sasang constitutions.
| No. | Identity | m/z | Mass error | Adduct | MS fragments | Fold change |
| Pathway | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SY/SE | SY/TE | SE/TE | ||||||||
| 1 | FA (20:0) | 311.2904 | -4.6 | M-H | 183 | 1.18 | 1.58 | 1.33 | 0.116 | Lipid metabolism |
| 2 | FA (20:4) | 303.2241 | -8.3 | M-H | 183 | 1.50 | 1.53 | 1.02 | 0.049 | Arachidonic acid metabolism |
| 3 | FA (22:5) | 329.2444 | -3.7 | M-H | 183 | 1.44 | 1.47 | 1.02 | 0.029 | Lipid metabolism |
| 4 | FA (22:6) | 327.2340 | 1.6 | M-H | 183 | 1.88 | 1.84 | 0.98 | 0.005 | Lipid metabolism |
| 5 | LPC (16:1) | 494.3254 | 0.72 | M+H | 476, 184, 104 | 1.26 | 1.17 | 0.93 | 0.026 | Lysolipid metabolism |
| 6 | LPC (18:0) | 568.3622 | 1.1 | M+COOH | 508, 283, 183, 153 | 1.25 | 1.27 | 1.02 | 0.064 | Lysolipid metabolism |
| 7 | LPE (16:0) | 452.2772 | -2.00 | M-H | 255, 214, 196 | 1.36 | 1.37 | 1.01 | 0.015 | Lysolipid metabolism |
| 8 | LPE (18:0) | 480.3096 | 5.2 | M-H | 283, 214, 196 | 1.28 | 1.27 | 1.00 | 0.054 | Lysolipid metabolism |
| 9 | LPG (16:0) | 507.2762 | 1.1 | M+Na | 449, 311, 155 | 0.93 | 0.94 | 1.01 | 0.088 | Lysolipid metabolism |
| 10 | LPI (18:0) | 599.3170 | -2.6 | M-H | 315, 283, 241 | 1.23 | 1.36 | 1.11 | 0.044 | Lysolipid metabolism |
| 11 | PC (32:0) | 734.5695 | -0.50 | M+H | 184 | 1.00 | 1.18 | 1.18 | 0.061 | Glycerophospholipid metabolism |
| 12 | PC (32:1) | 732.5528 | 1.68 | M+H | 184 | 1.46 | 1.15 | 0.79 | 0.040 | Glycerophospholipid metabolism |
| 13 | PC (33:1) | 746.5676 | -2.38 | M+H | 184 | 1.33 | 1.10 | 0.82 | 0.048 | Glycerophospholipid metabolism |
| 14 | PC (34:1) | 760.5878 | 2.22 | M+H | 184 | 1.23 | 1.05 | 0.86 | 0.033 | Glycerophospholipid metabolism |
| 15 | PC (36:1) | 788.6171 | 2.97 | M+H | 184 | 1.30 | 1.08 | 0.83 | 0.070 | Glycerophospholipid metabolism |
| 16 | PC (36:5) | 780.5535 | -0.81 | M+H | 184 | 1.63 | 1.19 | 0.73 | 0.072 | Glycerophospholipid metabolism |
| 17 | PC (36:6) | 778.5426 | 3.94 | M+H | 184 | 1.59 | 1.31 | 0.82 | 0.005 | Glycerophospholipid metabolism |
| 18 | PC (37:6) | 792.5567 | 2.40 | M+H | 184 | 1.13 | 1.04 | 0.93 | 0.041 | Glycerophospholipid metabolism |
| 19 | PC (38:3) | 812.6167 | -0.18 | M+H | 184 | 1.30 | 1.08 | 0.83 | 0.055 | Glycerophospholipid metabolism |
| 20 | PC (38:5) | 808.5840 | -1.64 | M+H | 184 | 1.35 | 1.13 | 0.84 | 0.084 | Glycerophospholipid metabolism |
| 21 | PC (38:6) | 806.5732 | 2.44 | M+H | 184 | 1.22 | 1.09 | 0.89 | 0.063 | Glycerophospholipid metabolism |
| 22 | SM (d32:1) | 675.5440 | -0.13 | M+H | 184 | 1.20 | 1.18 | 0.98 | 0.036 | Sphingolipid metabolism |
| 23 | SM (d34:1) | 703.5772 | 2.37 | M+H | 184 | 0.96 | 1.08 | 1.13 | 0.117 | Sphingolipid metabolism |
| 24 | SM (d35:1) | 717.5886 | -2.40 | M+H | 184 | 1.04 | 1.16 | 1.12 | 0.057 | Sphingolipid metabolism |
| 25 | SM (d41:1) | 801.6847 | -0.30 | M+H | 184 | 0.91 | 1.18 | 1.29 | 0.052 | Sphingolipid metabolism |
| 26 | SM (d42:1) | 815.7003 | -0.30 | M+H | 184 | 0.90 | 1.19 | 1.33 | 0.052 | Sphingolipid metabolism |
| 27 | SM (d43:1) | 829.7133 | -3.05 | M+H | 184 | 0.92 | 1.19 | 1.20 | 0.052 | Sphingolipid metabolism |
| 28 | 1-Deoxysphinganine | 286.3099 | -0.70 | M+H | 270 | 3.59 | 4.45 | 1.24 | 0.009 | Sphingolipid metabolism |
| 29 | Sphinganine (d17:0) | 288.2895 | -3.53 | M+H | 282, 264 | 1.09 | 1.46 | 1.34 | 0.197 | Sphingolipid metabolism |
| 30 | Sphinganine (d18:1) | 300.2907 | -2.44 | M+H | 310 | 1.93 | 1.91 | 0.99 | 0.034 | Sphingolipid metabolism |
| 31 | Sphinganine (d20:1) | 310.3120 | -0.25 | M+H | 268 | 1.44 | 1.24 | 0.87 | 0.040 | Sphingolipid metabolism |
| 32 | Cholesterol | 369.3534 | -0.17 | M+H | 369 | 0.98 | 0.94 | 0.96 | 0.061 | Primary bile acid biosynthesis |
| 33 | DG (32:0) | 591.4954 | -3.40 | M+Na | 551, 313, 257 | 0.90 | 1.17 | 1.30 | 0.012 | Glycerolipid metabolism |
| 34 | TG (50:1) | 850.7851 | -1.82 | M+NH4 | 603, 551 | 1.00 | 1.30 | 1.30 | 0.472 | Glycerolipid metabolism |
| 35 | TG (52:2) | 876.8014 | 4.19 | M+NH4 | 859, 841, 577 | 1.01 | 1.20 | 1.19 | 0.591 | Glycerolipid metabolism |
| 36 | TG (54:3) | 902.8162 | -2.55 | M+NH4 | 867, 603, 339 | 0.95 | 1.14 | 1.19 | 0.346 | Glycerolipid metabolism |
Fold change was calculated by dividing the mean of the peak intensity of each metabolite from each of the two groups. SY: Soyangin; TE: Taeeumin; SE: Soeumin. p value < 0.05.